This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Role of Statins in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2011 by University of Sao Paulo General Hospital.
Recruitment status was:  Recruiting
Information provided by:
University of Sao Paulo General Hospital Identifier:
First received: April 27, 2011
Last updated: May 2, 2011
Last verified: April 2011
Delayed ischemia caused by cerebral vasospasm remains a common cause of morbidity and mortality after aneurysmal subarachnoid hemorrhage. A great deal of drugs has been tested in the last years. Phase II randomized clinical trials have demonstrated that statin decreases the incidence of symptomatic cerebral vasospasm after spontaneous subarachnoid hemorrhage. Clinical, double blind, randomized controlled trials with placebo. Discussion: Even though some articles have shown that statins provide better prognosis, some issues remain in debate, e.g., treatment duration and the choice of the statin.

Condition Intervention Phase
Aneurysmal Subarachnoid Hemorrhage Drug: statin Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Role of Statins in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage

Resource links provided by NLM:

Further study details as provided by University of Sao Paulo General Hospital:

Primary Outcome Measures:
  • The role of statins in preventing cerebral vasospasm secondary to subarachnoid hemorrhage [ Time Frame: 6 months ]
    Diference in clinical outcome between patients who will or won't receive sinvastatin.

Estimated Enrollment: 80
Study Start Date: April 2011
Estimated Study Completion Date: February 2013
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Statin Drug: statin
Sinvastatin 80 mg per day - 21 days versus placebo


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age between 18 and 65 years old, Hunt-hess scale < 3

Exclusion Criteria:

  • Liver disfunction, previous use of statin, hunt-hess scale 4 or 5.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01346748

Contact: Flavio Romero 11-34594416
Contact: Flávio Romero 11-34594416

Hospital das Clínicas Recruiting
São Paulo, Brazil, 05445-000
Contact: Flávio Romero    11-34594416   
Principal Investigator: Eberval Figueiredo         
Principal Investigator: Flavio Romero         
Sponsors and Collaborators
University of Sao Paulo General Hospital
Principal Investigator: Eberval Figueiredo, PhD University of São Paulo
  More Information

Responsible Party: Eberval Gadelha Figueiredo, Neurology department of São Paulo University Identifier: NCT01346748     History of Changes
Other Study ID Numbers: 1268/09
Study First Received: April 27, 2011
Last Updated: May 2, 2011

Keywords provided by University of Sao Paulo General Hospital:
vasospasm prevention

Additional relevant MeSH terms:
Subarachnoid Hemorrhage
Vasospasm, Intracranial
Pathologic Processes
Intracranial Hemorrhages
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Lipid Regulating Agents processed this record on August 23, 2017